Equities analysts expect that Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) will report ($0.09) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics posted earnings per share of ($0.03) during the same quarter last year, which would suggest a negative year over year growth rate of 200%. The business is scheduled to report its next earnings results on Thursday, March 29th.
On average, analysts expect that Brainstorm Cell Therapeutics will report full year earnings of ($0.37) per share for the current fiscal year. For the next year, analysts anticipate that the company will report earnings of ($0.42) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Brainstorm Cell Therapeutics.
Get Brainstorm Cell Therapeutics alerts:
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter last year, the company posted ($0.09) EPS.
Several research analysts recently weighed in on the stock. ValuEngine downgraded shares of Brainstorm Cell Therapeutics…